Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye (ARISE-3)

Trial Profile

A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye (ARISE-3)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Timbetasin (Primary)
  • Indications Dry eyes
  • Focus Registrational; Therapeutic Use
  • Acronyms ARISE-3
  • Sponsors ReGenTree
  • Most Recent Events

    • 16 Oct 2019 According to a RegeneRx Biopharmaceuticals media release, the trial is progressing smoothly and GtreeBNT will continue discussions with potential strategic partners as the trial moves closer toward completion in the Summer of 2020.
    • 30 Sep 2019 According to a RegeneRx Biopharmaceuticals media release, the trial is enrolling patients on schedule and the anticipated completion of the trial is by the end of second quarter 2020.
    • 29 Jul 2019 According to a RegeneRx Biopharmaceuticals media release, data readout from this trial is expected in third quarter of 2020 to confirm data from previous trials
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top